Corcept Therapeutics Incorporated (CORT)

Short-term

Turnover ratios

The inventory turnover ratio for Corcept Therapeutics Incorporated has shown fluctuations over the past few years, ranging from as low as 0.26 to as high as 1.22. The company's inventory turnover improved in the most recent periods, reaching levels above 1. This indicates that the company is managing its inventory more efficiently, selling through its inventory at a faster rate.

The receivables turnover ratio data is not available for analysis, implying that there is a lack of information regarding how quickly the company collects its accounts receivable.

Similarly, the payables turnover ratio data is not provided, so it is unclear how quickly the company pays its suppliers.

In terms of the working capital turnover ratio, Corcept Therapeutics has shown an upward trend over the periods analyzed. The company's ability to generate revenue from its working capital has been improving, with the ratio consistently above 1 in the most recent periods. This suggests that the company is effectively utilizing its working capital to generate sales and operations.

Overall, while the inventory turnover and working capital turnover ratios demonstrate positive trends for Corcept Therapeutics, the lack of data for the receivables and payables turnover ratios limits a comprehensive assessment of the company's overall efficiency in managing its assets and liabilities.

---

Average number of days

Corcept Therapeutics Incorporated's Days of Inventory on Hand (DOH) ratio fluctuated significantly over the period from March 31, 2020, to December 31, 2024. The company started with a high DOH of 959.57 days on March 31, 2020, indicating that it held almost three years' worth of inventory. This figure decreased substantially by June 30, 2020, to 299.78 days and stayed relatively stable until the end of 2020.

However, there was a significant spike in the DOH ratio to 1,383.43 days by December 31, 2020, implying that the company experienced challenges in managing its inventory efficiently. The ratio gradually decreased over the following periods but remained elevated, indicating potential issues with inventory management.

From March 31, 2023, to December 31, 2024, the DOH ratio fluctuated within a range of 299.73 to 1,223.58 days, with no clear trend in inventory management efficiency. The company may need to implement strategies to optimize its inventory levels and improve operational efficiency.

Unfortunately, data on the Days of Sales Outstanding (DSO) and Number of Days of Payables ratios were not available, limiting a comprehensive analysis of Corcept Therapeutics Incorporated's activity ratios. It is essential for the company to provide additional information on these ratios to assess its overall liquidity and efficiency in managing receivables and payables effectively.

---

Long-term

The fixed asset turnover ratio for Corcept Therapeutics Incorporated has exhibited significant fluctuations over the analyzed periods. The ratio measures the efficiency of the company in generating sales revenue from its investment in fixed assets. The ratio ranged from a low of 116.78 to a high of 1,036.69 during the period, indicating varying levels of productivity in utilizing fixed assets to generate sales.

On the other hand, the total asset turnover ratio, which evaluates the firm's ability to generate sales in relation to its total assets, demonstrated a more stable trend over the same period. The ratio fluctuated within a narrower range, from 0.60 to 0.86, reflecting relatively consistent effectiveness in utilizing total assets to generate revenue.

Overall, analyzing both ratios in conjunction provides insights into Corcept Therapeutics' operational efficiency and asset utilization strategies. Investors and stakeholders may infer from these ratios the company's effectiveness in converting its investments in assets, both fixed and total, into sales revenue.